1. Home
  2. SON vs CRNX Comparison

SON vs CRNX Comparison

Compare SON & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sonoco Products Company

SON

Sonoco Products Company

HOLD

Current Price

$50.37

Market Cap

4.7B

ML Signal

HOLD

Logo Crinetics Pharmaceuticals Inc.

CRNX

Crinetics Pharmaceuticals Inc.

HOLD

Current Price

$35.26

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SON
CRNX
Founded
1899
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Containers/Packaging
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.7B
3.9B
IPO Year
2014
2018

Fundamental Metrics

Financial Performance
Metric
SON
CRNX
Price
$50.37
$35.26
Analyst Decision
Buy
Strong Buy
Analyst Count
8
9
Target Price
$63.00
$74.78
AVG Volume (30 Days)
768.2K
903.6K
Earning Date
04-21-2026
05-07-2026
Dividend Yield
4.09%
N/A
EPS Growth
510.30
N/A
EPS
10.07
N/A
Revenue
$7,518,753,000.00
$1,039,000.00
Revenue This Year
$0.03
$722.66
Revenue Next Year
$2.01
$183.79
P/E Ratio
$5.15
N/A
Revenue Growth
41.72
N/A
52 Week Low
$38.65
$24.10
52 Week High
$58.44
$57.99

Technical Indicators

Market Signals
Indicator
SON
CRNX
Relative Strength Index (RSI) 34.55 26.12
Support Level $43.24 $33.23
Resistance Level $55.00 $37.23
Average True Range (ATR) 1.37 1.50
MACD -0.62 -0.01
Stochastic Oscillator 0.00 3.41

Price Performance

Historical Comparison
SON
CRNX

About SON Sonoco Products Company

Over its 100-year-plus history, Sonoco Products has steadily assembled a diverse portfolio of industrial and consumer packaging product offerings such as flexible and rigid plastics, reels and spools, pallets, and composite cans. The company serves a variety of consumer and industrial end markets throughout North America. Sonoco has raised its dividend each year for more than 40 years.

About CRNX Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.

Share on Social Networks: